Side-by-side · Research reference

CerebrolysinvsMazdutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED11/65 cited

BPhase 3HUMAN-REVIEWED19/62 cited

Cerebrolysin

Porcine Brain-Derived Peptide Mix · Phase 3

30 mL/dayStandard doseAfridi 2026 Staszewski 2026

14–21 daysTreatment course

49% vs 35%mRS 0-2 at 12 moStaszewski 2026

IV infusion · 100-250 mL saline · Daily

Mazdutide

GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3

9 mgWeekly doseJi 2026

12.4%Weight lossAzam 2026

Phase 3Status (China)

SQ · Abdomen · Once WeeklyJi 2026

01Mechanism of Action

Parameter

Cerebrolysin

Mazdutide

Primary target

Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation

GLP-1 receptor and glucagon receptorAbdul 2026 Elmendorf 2026

Pathway

Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis

Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026 Abulehia 2026

Downstream effect

Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery

Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D

Feedback intact?

Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis

Yes — physiological receptor-mediated signaling preserved

Origin

Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids

Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity

Antibody development

Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented

—

02Dosage Protocols

Parameter

Cerebrolysin

Mazdutide

Standard dose (stroke)

30–50 mL / day IVStaszewski 2026 Afridi 2026

Most trials use 30 mL in 100-250 mL saline over 30-60 min.

—

Lower dose (dementia)

10–20 mL / day IV or IMKhatkova 2026

Chronic neurodegenerative conditions; intermittent courses.

—

High dose (TBI)

50 mL / day IVKobayashi 2025

CLINCH trial protocol for intracerebral hemorrhage.

—

Duration

10–21 days (acute); intermittent courses (chronic)

Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.

—

Timing (stroke)

Initiate within 12 hrs of symptom onset; up to 6 hrs optimal

Earlier initiation associated with better outcomes.

—

Adjunct to thrombectomy

30-50 mL daily × 10-14 days, starting day of EVT

Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.

—

Evidence basis

Phase 3 RCT + observational

Phase 2 RCT / Phase 3 ongoingJi 2026 Luo 2026

Administration route

IV infusion (preferred) or IM injection

IV allows higher doses; IM used in outpatient/chronic settings.

—

Phase 2 studied dose

—

9 mg / weekJi 2026

Highest efficacy dose in obesity trial (BMI ≥30 kg/m²).Ji 2026

Frequency

—

Once weeklyJi 2026 Luo 2026

Route

—

SubcutaneousJi 2026

Dose escalation

—

3 mg → 6 mg → 9 mg (titration schedule in trials)

Gradual escalation to minimize GI side effects.

Duration (trials)

—

24–48 weeks

Population

—

Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities

Phase 3 comparator

—

Semaglutide 1 mg/week (DREAMS-3 trial)Luo 2026

03Metabolic / Fat Loss Evidence

Parameter

Cerebrolysin

Mazdutide

Percentage body weight loss

—

12.4% (pooled meta-analysis, 9 mg dose)

95% CI: -16.15% to -8.68%, random-effects model.Azam 2026

Absolute weight loss

—

9.8 kg (mean)Azam 2026

95% CI: -13.15 to -6.37 kg.Azam 2026

Responder rate (≥10% loss)

—

Not explicitly reported in available abstracts

Mechanism

—

Appetite suppression (GLP-1) + energy expenditure (glucagon)Elmendorf 2026

BMI reduction

—

Significant reduction in Chinese adults BMI ≥30 kg/m²Ji 2026

Visceral fat

—

Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)

Glycemic improvement

—

HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)

Comparator efficacy

—

Head-to-head vs semaglutide 1 mg (Phase 3 pending publication)Luo 2026

Key publications

—

Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026

04Side Effects & Safety

Parameter

Cerebrolysin

Mazdutide

Injection site reaction

Mild pain, erythema (IM route)

—

Infusion reaction

Rare: flushing, transient hypotension during rapid IV

—

Agitation / Restlessness

Reported in <5% of patients; typically mild, self-limited

—

Headache

Mild, transient; incidence not significantly elevated vs placeboPatel 2025

—

Serious adverse events

No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)

—

Hemorrhagic transformation

Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025

—

Mortality

No increase; meta-analysis RR 0.89 (0.68-1.18)

—

Allergic reaction

Rare; porcine origin theoretically immunogenic but clinically insignificant

—

Seizure risk

Not elevated; safe in epilepsy populations

—

Gastrointestinal symptoms

—

Nausea, vomiting, diarrhea (most common, GLP-1 effect)

Injection site reactions

—

Erythema, pruritus, local discomfort

Hypoglycemia

—

Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas

Cardiovascular effects

—

Increased heart rate (glucagon effect, transient)

Pancreatitis risk

—

Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain

Thyroid C-cell tumors

—

Black box warning for GLP-1 class (rodent data); human relevance unclear

Gallbladder disease

—

Cholelithiasis, cholecystitis (rapid weight loss effect)

Tolerability

—

Generally well-tolerated; GI effects diminish with dose titration

Absolute Contraindications

Cerebrolysin

·Known hypersensitivity to porcine-derived products
·Active seizure disorder (relative — caution advised)

Mazdutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
·Hypersensitivity to mazdutide or excipients
·Pregnancy

Relative Contraindications

Cerebrolysin

·Severe renal impairment (amino acid load — monitor)
·Pregnancy / lactation (insufficient safety data)

Mazdutide

·History of pancreatitis
·Severe gastroparesis or GI motility disorders
·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
·Renal impairment (limited data, use with caution)

05Administration Protocol

Parameter

Cerebrolysin

Mazdutide

1. Preparation (IV infusion)

Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.

Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.

2. Infusion rate

Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.

Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.

3. IM injection (alternative)

For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.

Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.

4. Timing

Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.

Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.

5. Storage

Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.

Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.

6. Co-administration

Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.

—

06Stack Synergy

Cerebrolysin

+ Semax

Moderate

View Semax →

Cerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.

Cerebrolysin: 30 mL IV daily × 10-14 days
Semax: 300-600 mcg intranasal BID × 10-14 days
Timing: Concurrent during acute recovery phase
Primary benefit: Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI

+ BPC-157

Multi-pathway

View BPC-157 →

Cerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.

Cerebrolysin: 30-50 mL IV daily × 14 days
BPC-157: 250-500 mcg SQ daily × 14-28 days
Timing: Initiate both within 24-48 hrs of injury
Primary benefit: Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery

Mazdutide

— no documented stacks